Immune Evasion of Human Lung Carcinoma Cell A549 Suppressed by Human Lymphoma Cell Jurkat via Fas/FasL Pathway

Background and objective Tumor escape from the host immune system has been a major problem in immunotherapy of human malignancies. FasL/Fas-induced apoptosis plays an important role in various immunological processes. The aim of this study is to investigate the immune evasion in human lung carcinoma...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Hongmei WANG [verfasserIn] Guoqiang ZHANG [verfasserIn] Jigang DAI [verfasserIn] Jiaxin MIN [verfasserIn]

Format:	E-Artikel
Sprache:	Chinesisch

Erschienen:	2010

Schlagwörter:	Lung neoplasms Apoptosis Immune evasion

Übergeordnetes Werk:	In: Chinese Journal of Lung Cancer - Chinese Anti-Cancer Association; Chinese Antituberculosis Association, 2008, 13(2010), 7, Seite 681-685
Übergeordnetes Werk:	volume:13 ; year:2010 ; number:7 ; pages:681-685

Links:	Link aufrufen Link aufrufen Journal toc Journal toc

Katalog-ID:	DOAJ079634311

Internformat


LEADER	01000naa a22002652 4500
001	DOAJ079634311
003	DE-627
005	20230307020638.0
007	cr uuu---uuuuu
008	230307s2010 xx \|\|\|\|\|o 00\| \|\|chi c
035			\|a (DE-627)DOAJ079634311
035			\|a (DE-599)DOAJ6130e906798c47b08120406f169aff82
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a chi
050		0	\|a RC254-282
100	0		\|a Hongmei WANG \|e verfasserin \|4 aut
245	1	0	\|a Immune Evasion of Human Lung Carcinoma Cell A549 Suppressed by Human Lymphoma Cell Jurkat via Fas/FasL Pathway
264		1	\|c 2010
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a Background and objective Tumor escape from the host immune system has been a major problem in immunotherapy of human malignancies. FasL/Fas-induced apoptosis plays an important role in various immunological processes. The aim of this study is to investigate the immune evasion in human lung carcinoma cell A549 induced by human lymphoma cell Jurkat via Fas/FasL pathway. Methods Jurkat cells and A549 cells were co-cultured at different proportions. The apoptotic rates of A549 cells were determined by flow cytometry (FCM). Protein levels of Fas, FasL and Caspase-8 in A549 cells were detected by Western blot. Results Survival rates of A549 cells gradually decreased and apoptotic rates of A549 cells were significantly enhanced along with ratio increasing between Jurkat and A549. Meanwhile, the protein levels of Fas and Caspase-8 gradually increased in A549 cells, and the protein levels of FasL had no significant difference in all groups. Conclusion The Jurkat cells might decrease the survival rates of A549 cells and enhanced its apoptosis and immune evasion partly via Fas/FasL pathway.
650		4	\|a Lung neoplasms
650		4	\|a Apoptosis
650		4	\|a Immune evasion
653		0	\|a Neoplasms. Tumors. Oncology. Including cancer and carcinogens
700	0		\|a Guoqiang ZHANG \|e verfasserin \|4 aut
700	0		\|a Jigang DAI \|e verfasserin \|4 aut
700	0		\|a Jiaxin MIN \|e verfasserin \|4 aut
773	0	8	\|i In \|t Chinese Journal of Lung Cancer \|d Chinese Anti-Cancer Association; Chinese Antituberculosis Association, 2008 \|g 13(2010), 7, Seite 681-685 \|w (DE-627)572421125 \|w (DE-600)2438672-8 \|x 19996187 \|7 nnns
773	1	8	\|g volume:13 \|g year:2010 \|g number:7 \|g pages:681-685
856	4	0	\|u https://doaj.org/article/6130e906798c47b08120406f169aff82 \|z kostenfrei
856	4	0	\|u http://www.lungca.org/index.php?journal=01&page=article&op=viewFile&path[]=10.3779%2Fj.issn.1009-3419.2010.07.05&path[]=1602 \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/1009-3419 \|y Journal toc \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/1999-6187 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_150
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2005
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_2106
912			\|a GBV_ILN_2232
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 13 \|j 2010 \|e 7 \|h 681-685

Indexfelder

author_variant	h w hw g z gz j d jd j m jm
matchkey_str	article:19996187:2010----::muevsoohmnugacnmcla4sprsebhmnypoae
hierarchy_sort_str	2010
callnumber-subject-code	RC
publishDate	2010
allfields	(DE-627)DOAJ079634311 (DE-599)DOAJ6130e906798c47b08120406f169aff82 DE-627 ger DE-627 rakwb chi RC254-282 Hongmei WANG verfasserin aut Immune Evasion of Human Lung Carcinoma Cell A549 Suppressed by Human Lymphoma Cell Jurkat via Fas/FasL Pathway 2010 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background and objective Tumor escape from the host immune system has been a major problem in immunotherapy of human malignancies. FasL/Fas-induced apoptosis plays an important role in various immunological processes. The aim of this study is to investigate the immune evasion in human lung carcinoma cell A549 induced by human lymphoma cell Jurkat via Fas/FasL pathway. Methods Jurkat cells and A549 cells were co-cultured at different proportions. The apoptotic rates of A549 cells were determined by flow cytometry (FCM). Protein levels of Fas, FasL and Caspase-8 in A549 cells were detected by Western blot. Results Survival rates of A549 cells gradually decreased and apoptotic rates of A549 cells were significantly enhanced along with ratio increasing between Jurkat and A549. Meanwhile, the protein levels of Fas and Caspase-8 gradually increased in A549 cells, and the protein levels of FasL had no significant difference in all groups. Conclusion The Jurkat cells might decrease the survival rates of A549 cells and enhanced its apoptosis and immune evasion partly via Fas/FasL pathway. Lung neoplasms Apoptosis Immune evasion Neoplasms. Tumors. Oncology. Including cancer and carcinogens Guoqiang ZHANG verfasserin aut Jigang DAI verfasserin aut Jiaxin MIN verfasserin aut In Chinese Journal of Lung Cancer Chinese Anti-Cancer Association; Chinese Antituberculosis Association, 2008 13(2010), 7, Seite 681-685 (DE-627)572421125 (DE-600)2438672-8 19996187 nnns volume:13 year:2010 number:7 pages:681-685 https://doaj.org/article/6130e906798c47b08120406f169aff82 kostenfrei http://www.lungca.org/index.php?journal=01&page=article&op=viewFile&path[]=10.3779%2Fj.issn.1009-3419.2010.07.05&path[]=1602 kostenfrei https://doaj.org/toc/1009-3419 Journal toc kostenfrei https://doaj.org/toc/1999-6187 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_150 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2014 GBV_ILN_2106 GBV_ILN_2232 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 13 2010 7 681-685
spelling	(DE-627)DOAJ079634311 (DE-599)DOAJ6130e906798c47b08120406f169aff82 DE-627 ger DE-627 rakwb chi RC254-282 Hongmei WANG verfasserin aut Immune Evasion of Human Lung Carcinoma Cell A549 Suppressed by Human Lymphoma Cell Jurkat via Fas/FasL Pathway 2010 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background and objective Tumor escape from the host immune system has been a major problem in immunotherapy of human malignancies. FasL/Fas-induced apoptosis plays an important role in various immunological processes. The aim of this study is to investigate the immune evasion in human lung carcinoma cell A549 induced by human lymphoma cell Jurkat via Fas/FasL pathway. Methods Jurkat cells and A549 cells were co-cultured at different proportions. The apoptotic rates of A549 cells were determined by flow cytometry (FCM). Protein levels of Fas, FasL and Caspase-8 in A549 cells were detected by Western blot. Results Survival rates of A549 cells gradually decreased and apoptotic rates of A549 cells were significantly enhanced along with ratio increasing between Jurkat and A549. Meanwhile, the protein levels of Fas and Caspase-8 gradually increased in A549 cells, and the protein levels of FasL had no significant difference in all groups. Conclusion The Jurkat cells might decrease the survival rates of A549 cells and enhanced its apoptosis and immune evasion partly via Fas/FasL pathway. Lung neoplasms Apoptosis Immune evasion Neoplasms. Tumors. Oncology. Including cancer and carcinogens Guoqiang ZHANG verfasserin aut Jigang DAI verfasserin aut Jiaxin MIN verfasserin aut In Chinese Journal of Lung Cancer Chinese Anti-Cancer Association; Chinese Antituberculosis Association, 2008 13(2010), 7, Seite 681-685 (DE-627)572421125 (DE-600)2438672-8 19996187 nnns volume:13 year:2010 number:7 pages:681-685 https://doaj.org/article/6130e906798c47b08120406f169aff82 kostenfrei http://www.lungca.org/index.php?journal=01&page=article&op=viewFile&path[]=10.3779%2Fj.issn.1009-3419.2010.07.05&path[]=1602 kostenfrei https://doaj.org/toc/1009-3419 Journal toc kostenfrei https://doaj.org/toc/1999-6187 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_150 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2014 GBV_ILN_2106 GBV_ILN_2232 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 13 2010 7 681-685
allfields_unstemmed	(DE-627)DOAJ079634311 (DE-599)DOAJ6130e906798c47b08120406f169aff82 DE-627 ger DE-627 rakwb chi RC254-282 Hongmei WANG verfasserin aut Immune Evasion of Human Lung Carcinoma Cell A549 Suppressed by Human Lymphoma Cell Jurkat via Fas/FasL Pathway 2010 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background and objective Tumor escape from the host immune system has been a major problem in immunotherapy of human malignancies. FasL/Fas-induced apoptosis plays an important role in various immunological processes. The aim of this study is to investigate the immune evasion in human lung carcinoma cell A549 induced by human lymphoma cell Jurkat via Fas/FasL pathway. Methods Jurkat cells and A549 cells were co-cultured at different proportions. The apoptotic rates of A549 cells were determined by flow cytometry (FCM). Protein levels of Fas, FasL and Caspase-8 in A549 cells were detected by Western blot. Results Survival rates of A549 cells gradually decreased and apoptotic rates of A549 cells were significantly enhanced along with ratio increasing between Jurkat and A549. Meanwhile, the protein levels of Fas and Caspase-8 gradually increased in A549 cells, and the protein levels of FasL had no significant difference in all groups. Conclusion The Jurkat cells might decrease the survival rates of A549 cells and enhanced its apoptosis and immune evasion partly via Fas/FasL pathway. Lung neoplasms Apoptosis Immune evasion Neoplasms. Tumors. Oncology. Including cancer and carcinogens Guoqiang ZHANG verfasserin aut Jigang DAI verfasserin aut Jiaxin MIN verfasserin aut In Chinese Journal of Lung Cancer Chinese Anti-Cancer Association; Chinese Antituberculosis Association, 2008 13(2010), 7, Seite 681-685 (DE-627)572421125 (DE-600)2438672-8 19996187 nnns volume:13 year:2010 number:7 pages:681-685 https://doaj.org/article/6130e906798c47b08120406f169aff82 kostenfrei http://www.lungca.org/index.php?journal=01&page=article&op=viewFile&path[]=10.3779%2Fj.issn.1009-3419.2010.07.05&path[]=1602 kostenfrei https://doaj.org/toc/1009-3419 Journal toc kostenfrei https://doaj.org/toc/1999-6187 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_150 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2014 GBV_ILN_2106 GBV_ILN_2232 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 13 2010 7 681-685
allfieldsGer	(DE-627)DOAJ079634311 (DE-599)DOAJ6130e906798c47b08120406f169aff82 DE-627 ger DE-627 rakwb chi RC254-282 Hongmei WANG verfasserin aut Immune Evasion of Human Lung Carcinoma Cell A549 Suppressed by Human Lymphoma Cell Jurkat via Fas/FasL Pathway 2010 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background and objective Tumor escape from the host immune system has been a major problem in immunotherapy of human malignancies. FasL/Fas-induced apoptosis plays an important role in various immunological processes. The aim of this study is to investigate the immune evasion in human lung carcinoma cell A549 induced by human lymphoma cell Jurkat via Fas/FasL pathway. Methods Jurkat cells and A549 cells were co-cultured at different proportions. The apoptotic rates of A549 cells were determined by flow cytometry (FCM). Protein levels of Fas, FasL and Caspase-8 in A549 cells were detected by Western blot. Results Survival rates of A549 cells gradually decreased and apoptotic rates of A549 cells were significantly enhanced along with ratio increasing between Jurkat and A549. Meanwhile, the protein levels of Fas and Caspase-8 gradually increased in A549 cells, and the protein levels of FasL had no significant difference in all groups. Conclusion The Jurkat cells might decrease the survival rates of A549 cells and enhanced its apoptosis and immune evasion partly via Fas/FasL pathway. Lung neoplasms Apoptosis Immune evasion Neoplasms. Tumors. Oncology. Including cancer and carcinogens Guoqiang ZHANG verfasserin aut Jigang DAI verfasserin aut Jiaxin MIN verfasserin aut In Chinese Journal of Lung Cancer Chinese Anti-Cancer Association; Chinese Antituberculosis Association, 2008 13(2010), 7, Seite 681-685 (DE-627)572421125 (DE-600)2438672-8 19996187 nnns volume:13 year:2010 number:7 pages:681-685 https://doaj.org/article/6130e906798c47b08120406f169aff82 kostenfrei http://www.lungca.org/index.php?journal=01&page=article&op=viewFile&path[]=10.3779%2Fj.issn.1009-3419.2010.07.05&path[]=1602 kostenfrei https://doaj.org/toc/1009-3419 Journal toc kostenfrei https://doaj.org/toc/1999-6187 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_150 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2014 GBV_ILN_2106 GBV_ILN_2232 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 13 2010 7 681-685
allfieldsSound	(DE-627)DOAJ079634311 (DE-599)DOAJ6130e906798c47b08120406f169aff82 DE-627 ger DE-627 rakwb chi RC254-282 Hongmei WANG verfasserin aut Immune Evasion of Human Lung Carcinoma Cell A549 Suppressed by Human Lymphoma Cell Jurkat via Fas/FasL Pathway 2010 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background and objective Tumor escape from the host immune system has been a major problem in immunotherapy of human malignancies. FasL/Fas-induced apoptosis plays an important role in various immunological processes. The aim of this study is to investigate the immune evasion in human lung carcinoma cell A549 induced by human lymphoma cell Jurkat via Fas/FasL pathway. Methods Jurkat cells and A549 cells were co-cultured at different proportions. The apoptotic rates of A549 cells were determined by flow cytometry (FCM). Protein levels of Fas, FasL and Caspase-8 in A549 cells were detected by Western blot. Results Survival rates of A549 cells gradually decreased and apoptotic rates of A549 cells were significantly enhanced along with ratio increasing between Jurkat and A549. Meanwhile, the protein levels of Fas and Caspase-8 gradually increased in A549 cells, and the protein levels of FasL had no significant difference in all groups. Conclusion The Jurkat cells might decrease the survival rates of A549 cells and enhanced its apoptosis and immune evasion partly via Fas/FasL pathway. Lung neoplasms Apoptosis Immune evasion Neoplasms. Tumors. Oncology. Including cancer and carcinogens Guoqiang ZHANG verfasserin aut Jigang DAI verfasserin aut Jiaxin MIN verfasserin aut In Chinese Journal of Lung Cancer Chinese Anti-Cancer Association; Chinese Antituberculosis Association, 2008 13(2010), 7, Seite 681-685 (DE-627)572421125 (DE-600)2438672-8 19996187 nnns volume:13 year:2010 number:7 pages:681-685 https://doaj.org/article/6130e906798c47b08120406f169aff82 kostenfrei http://www.lungca.org/index.php?journal=01&page=article&op=viewFile&path[]=10.3779%2Fj.issn.1009-3419.2010.07.05&path[]=1602 kostenfrei https://doaj.org/toc/1009-3419 Journal toc kostenfrei https://doaj.org/toc/1999-6187 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_150 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2014 GBV_ILN_2106 GBV_ILN_2232 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 13 2010 7 681-685
language	Chinese
source	In Chinese Journal of Lung Cancer 13(2010), 7, Seite 681-685 volume:13 year:2010 number:7 pages:681-685
sourceStr	In Chinese Journal of Lung Cancer 13(2010), 7, Seite 681-685 volume:13 year:2010 number:7 pages:681-685
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	Lung neoplasms Apoptosis Immune evasion Neoplasms. Tumors. Oncology. Including cancer and carcinogens
isfreeaccess_bool	true
container_title	Chinese Journal of Lung Cancer
authorswithroles_txt_mv	Hongmei WANG @@aut@@ Guoqiang ZHANG @@aut@@ Jigang DAI @@aut@@ Jiaxin MIN @@aut@@
publishDateDaySort_date	2010-01-01T00:00:00Z
hierarchy_top_id	572421125
id	DOAJ079634311
language_de	chinesisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">DOAJ079634311</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230307020638.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230307s2010 xx \|\|\|\|\|o 00\| \|\|chi c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ079634311</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ6130e906798c47b08120406f169aff82</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">chi</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC254-282</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Hongmei WANG</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Immune Evasion of Human Lung Carcinoma Cell A549 Suppressed by Human Lymphoma Cell Jurkat via Fas/FasL Pathway</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2010</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background and objective Tumor escape from the host immune system has been a major problem in immunotherapy of human malignancies. FasL/Fas-induced apoptosis plays an important role in various immunological processes. The aim of this study is to investigate the immune evasion in human lung carcinoma cell A549 induced by human lymphoma cell Jurkat via Fas/FasL pathway. Methods Jurkat cells and A549 cells were co-cultured at different proportions. The apoptotic rates of A549 cells were determined by flow cytometry (FCM). Protein levels of Fas, FasL and Caspase-8 in A549 cells were detected by Western blot. Results Survival rates of A549 cells gradually decreased and apoptotic rates of A549 cells were significantly enhanced along with ratio increasing between Jurkat and A549. Meanwhile, the protein levels of Fas and Caspase-8 gradually increased in A549 cells, and the protein levels of FasL had no significant difference in all groups. Conclusion The Jurkat cells might decrease the survival rates of A549 cells and enhanced its apoptosis and immune evasion partly via Fas/FasL pathway.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Lung neoplasms</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Apoptosis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Immune evasion</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Neoplasms. Tumors. Oncology. Including cancer and carcinogens</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Guoqiang ZHANG</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jigang DAI</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jiaxin MIN</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Chinese Journal of Lung Cancer</subfield><subfield code="d">Chinese Anti-Cancer Association; Chinese Antituberculosis Association, 2008</subfield><subfield code="g">13(2010), 7, Seite 681-685</subfield><subfield code="w">(DE-627)572421125</subfield><subfield code="w">(DE-600)2438672-8</subfield><subfield code="x">19996187</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:13</subfield><subfield code="g">year:2010</subfield><subfield code="g">number:7</subfield><subfield code="g">pages:681-685</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/6130e906798c47b08120406f169aff82</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.lungca.org/index.php?journal=01&page=article&op=viewFile&path[]=10.3779%2Fj.issn.1009-3419.2010.07.05&path[]=1602</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1009-3419</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1999-6187</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_150</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2106</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2232</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">13</subfield><subfield code="j">2010</subfield><subfield code="e">7</subfield><subfield code="h">681-685</subfield></datafield></record></collection>
callnumber-first	R - Medicine
author	Hongmei WANG
spellingShingle	Hongmei WANG misc RC254-282 misc Lung neoplasms misc Apoptosis misc Immune evasion misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens Immune Evasion of Human Lung Carcinoma Cell A549 Suppressed by Human Lymphoma Cell Jurkat via Fas/FasL Pathway
authorStr	Hongmei WANG
ppnlink_with_tag_str_mv	@@773@@(DE-627)572421125
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut aut
collection	DOAJ
remote_str	true
callnumber-label	RC254-282
illustrated	Not Illustrated
issn	19996187
topic_title	RC254-282 Immune Evasion of Human Lung Carcinoma Cell A549 Suppressed by Human Lymphoma Cell Jurkat via Fas/FasL Pathway Lung neoplasms Apoptosis Immune evasion
topic	misc RC254-282 misc Lung neoplasms misc Apoptosis misc Immune evasion misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens
topic_unstemmed	misc RC254-282 misc Lung neoplasms misc Apoptosis misc Immune evasion misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens
topic_browse	misc RC254-282 misc Lung neoplasms misc Apoptosis misc Immune evasion misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Chinese Journal of Lung Cancer
hierarchy_parent_id	572421125
hierarchy_top_title	Chinese Journal of Lung Cancer
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)572421125 (DE-600)2438672-8
title	Immune Evasion of Human Lung Carcinoma Cell A549 Suppressed by Human Lymphoma Cell Jurkat via Fas/FasL Pathway
ctrlnum	(DE-627)DOAJ079634311 (DE-599)DOAJ6130e906798c47b08120406f169aff82
title_full	Immune Evasion of Human Lung Carcinoma Cell A549 Suppressed by Human Lymphoma Cell Jurkat via Fas/FasL Pathway
author_sort	Hongmei WANG
journal	Chinese Journal of Lung Cancer
journalStr	Chinese Journal of Lung Cancer
callnumber-first-code	R
lang_code	chi
isOA_bool	true
recordtype	marc
publishDateSort	2010
contenttype_str_mv	txt
container_start_page	681
author_browse	Hongmei WANG Guoqiang ZHANG Jigang DAI Jiaxin MIN
container_volume	13
class	RC254-282
format_se	Elektronische Aufsätze
author-letter	Hongmei WANG
author2-role	verfasserin
title_sort	immune evasion of human lung carcinoma cell a549 suppressed by human lymphoma cell jurkat via fas/fasl pathway
callnumber	RC254-282
title_auth	Immune Evasion of Human Lung Carcinoma Cell A549 Suppressed by Human Lymphoma Cell Jurkat via Fas/FasL Pathway
abstract	Background and objective Tumor escape from the host immune system has been a major problem in immunotherapy of human malignancies. FasL/Fas-induced apoptosis plays an important role in various immunological processes. The aim of this study is to investigate the immune evasion in human lung carcinoma cell A549 induced by human lymphoma cell Jurkat via Fas/FasL pathway. Methods Jurkat cells and A549 cells were co-cultured at different proportions. The apoptotic rates of A549 cells were determined by flow cytometry (FCM). Protein levels of Fas, FasL and Caspase-8 in A549 cells were detected by Western blot. Results Survival rates of A549 cells gradually decreased and apoptotic rates of A549 cells were significantly enhanced along with ratio increasing between Jurkat and A549. Meanwhile, the protein levels of Fas and Caspase-8 gradually increased in A549 cells, and the protein levels of FasL had no significant difference in all groups. Conclusion The Jurkat cells might decrease the survival rates of A549 cells and enhanced its apoptosis and immune evasion partly via Fas/FasL pathway.
abstractGer	Background and objective Tumor escape from the host immune system has been a major problem in immunotherapy of human malignancies. FasL/Fas-induced apoptosis plays an important role in various immunological processes. The aim of this study is to investigate the immune evasion in human lung carcinoma cell A549 induced by human lymphoma cell Jurkat via Fas/FasL pathway. Methods Jurkat cells and A549 cells were co-cultured at different proportions. The apoptotic rates of A549 cells were determined by flow cytometry (FCM). Protein levels of Fas, FasL and Caspase-8 in A549 cells were detected by Western blot. Results Survival rates of A549 cells gradually decreased and apoptotic rates of A549 cells were significantly enhanced along with ratio increasing between Jurkat and A549. Meanwhile, the protein levels of Fas and Caspase-8 gradually increased in A549 cells, and the protein levels of FasL had no significant difference in all groups. Conclusion The Jurkat cells might decrease the survival rates of A549 cells and enhanced its apoptosis and immune evasion partly via Fas/FasL pathway.
abstract_unstemmed	Background and objective Tumor escape from the host immune system has been a major problem in immunotherapy of human malignancies. FasL/Fas-induced apoptosis plays an important role in various immunological processes. The aim of this study is to investigate the immune evasion in human lung carcinoma cell A549 induced by human lymphoma cell Jurkat via Fas/FasL pathway. Methods Jurkat cells and A549 cells were co-cultured at different proportions. The apoptotic rates of A549 cells were determined by flow cytometry (FCM). Protein levels of Fas, FasL and Caspase-8 in A549 cells were detected by Western blot. Results Survival rates of A549 cells gradually decreased and apoptotic rates of A549 cells were significantly enhanced along with ratio increasing between Jurkat and A549. Meanwhile, the protein levels of Fas and Caspase-8 gradually increased in A549 cells, and the protein levels of FasL had no significant difference in all groups. Conclusion The Jurkat cells might decrease the survival rates of A549 cells and enhanced its apoptosis and immune evasion partly via Fas/FasL pathway.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_150 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2014 GBV_ILN_2106 GBV_ILN_2232 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
container_issue	7
title_short	Immune Evasion of Human Lung Carcinoma Cell A549 Suppressed by Human Lymphoma Cell Jurkat via Fas/FasL Pathway
url	https://doaj.org/article/6130e906798c47b08120406f169aff82 http://www.lungca.org/index.php?journal=01&page=article&op=viewFile&path[]=10.3779%2Fj.issn.1009-3419.2010.07.05&path[]=1602 https://doaj.org/toc/1009-3419 https://doaj.org/toc/1999-6187
remote_bool	true
author2	Guoqiang ZHANG Jigang DAI Jiaxin MIN
author2Str	Guoqiang ZHANG Jigang DAI Jiaxin MIN
ppnlink	572421125
callnumber-subject	RC - Internal Medicine
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
callnumber-a	RC254-282
up_date	2024-07-04T00:15:44.723Z
_version_	1803605397707161600
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">DOAJ079634311</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230307020638.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230307s2010 xx \|\|\|\|\|o 00\| \|\|chi c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ079634311</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ6130e906798c47b08120406f169aff82</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">chi</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC254-282</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Hongmei WANG</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Immune Evasion of Human Lung Carcinoma Cell A549 Suppressed by Human Lymphoma Cell Jurkat via Fas/FasL Pathway</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2010</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background and objective Tumor escape from the host immune system has been a major problem in immunotherapy of human malignancies. FasL/Fas-induced apoptosis plays an important role in various immunological processes. The aim of this study is to investigate the immune evasion in human lung carcinoma cell A549 induced by human lymphoma cell Jurkat via Fas/FasL pathway. Methods Jurkat cells and A549 cells were co-cultured at different proportions. The apoptotic rates of A549 cells were determined by flow cytometry (FCM). Protein levels of Fas, FasL and Caspase-8 in A549 cells were detected by Western blot. Results Survival rates of A549 cells gradually decreased and apoptotic rates of A549 cells were significantly enhanced along with ratio increasing between Jurkat and A549. Meanwhile, the protein levels of Fas and Caspase-8 gradually increased in A549 cells, and the protein levels of FasL had no significant difference in all groups. Conclusion The Jurkat cells might decrease the survival rates of A549 cells and enhanced its apoptosis and immune evasion partly via Fas/FasL pathway.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Lung neoplasms</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Apoptosis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Immune evasion</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Neoplasms. Tumors. Oncology. Including cancer and carcinogens</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Guoqiang ZHANG</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jigang DAI</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jiaxin MIN</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Chinese Journal of Lung Cancer</subfield><subfield code="d">Chinese Anti-Cancer Association; Chinese Antituberculosis Association, 2008</subfield><subfield code="g">13(2010), 7, Seite 681-685</subfield><subfield code="w">(DE-627)572421125</subfield><subfield code="w">(DE-600)2438672-8</subfield><subfield code="x">19996187</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:13</subfield><subfield code="g">year:2010</subfield><subfield code="g">number:7</subfield><subfield code="g">pages:681-685</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/6130e906798c47b08120406f169aff82</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.lungca.org/index.php?journal=01&page=article&op=viewFile&path[]=10.3779%2Fj.issn.1009-3419.2010.07.05&path[]=1602</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1009-3419</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1999-6187</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_150</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2106</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2232</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">13</subfield><subfield code="j">2010</subfield><subfield code="e">7</subfield><subfield code="h">681-685</subfield></datafield></record></collection>
score	7.4001446

Nicht das Richtige dabei?

Schreiben Sie uns!

Immune Evasion of Human Lung Carcinoma Cell A549 Suppressed by Human Lymphoma Cell Jurkat via Fas/FasL Pathway

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?